Kimball’s $103M Play for Helvoet: Forging the Future of Medical Networks

JASPER, IN – July 01, 2026 – In a move that signals a profound strategic pivot, Indiana-based Kimball Electronics has acquired European polymer specialist Helvoet Polymer Technologies B.V. for approximately $103 million (€90 million). While on the surface a standard corporate acquisition, this deal is a critical indicator of a deeper trend: the race to build the physical, often invisible, infrastructure that will underpin the next generation of global healthcare. This isn't just about expanding manufacturing; it's about controlling the essential building blocks for the intelligent networks of diagnostics, microfluidics, and drug delivery systems.

For years, Kimball Electronics has been known as a global electronics manufacturer. But this acquisition is the most definitive step yet in its deliberate transformation into a comprehensive medical Contract Development and Manufacturing Organization (CDMO). By integrating Helvoet’s deep expertise in high-performance polymers and elastomers, Kimball is moving beyond the circuit board to assemble the complete architecture of modern medical devices.

A Calculated Leap into Global Medical Dominance

This acquisition was no impulse buy. According to Kimball's CEO, Richard D. Phillips, it is the culmination of a multi-year strategy involving the divestiture of non-core assets and a concerted effort to strengthen the company’s balance sheet. This disciplined preparation allowed Kimball to seize a high-value opportunity, acquiring Helvoet at a valuation of approximately 9 times its estimated 2026 adjusted EBITDA—a figure considered attractive within the specialized CDMO sector. The deal, funded through cash and existing credit lines, is expected to be accretive to Kimball's adjusted earnings by fiscal year 2027 and boost sales in its medical vertical by a low double-digit percentage.

Prior to the deal, Kimball showed strong financial health, with a market capitalization over $600 million, a debt-to-equity ratio of just 0.31, and what analysts noted as a strong free cash flow yield. This stability provided the foundation for what Phillips described as acquiring "exactly the type of acquisition we’ve been building toward." He highlighted Helvoet's role in serving "blue-chip customers in the fastest-growing segments of healthcare," a clear sign that this move is about capturing future growth, not just present market share. The strategy is clear: fuse Kimball’s global electronics manufacturing scale with Helvoet’s niche, high-margin specialization to create a dominant force in the medical CMO landscape.

Expanding the Network: Europe and India as New Frontiers

The acquisition geographically redraws Kimball’s operational map, creating a more resilient and versatile global supply chain. With Helvoet’s primary manufacturing facilities in Tilburg, Netherlands, and Pune, India, Kimball instantly gains a robust European foothold and a critical entry point into the burgeoning Indian market. This is more than just adding dots on a map; it's about building regional nodes in the global medical device network, reducing logistical friction and increasing responsiveness to local market demands.

The Indian facility is particularly significant. Helvoet’s Indian subsidiary already generates over $20 million in annual revenue and recently launched an automated high-volume production line for Health Tech components. This move positions Kimball to tap into one of the world's fastest-growing healthcare markets, not just as a supplier but as a local manufacturing partner. Meanwhile, the European presence in the Netherlands provides proximity to a highly regulated, high-value market known for its stringent quality demands. As Eveline Hogenkamp, CEO of Helvoet, noted, the partnership is a powerful strategic fit. "Their Indianapolis facility, customer relationships, and operational capabilities are precisely what we need to scale our U.S. presence and win larger, more complex programs," she stated, highlighting the two-way synergy. Kimball plans to leverage its own new Indianapolis plant to serve Helvoet’s existing U.S. customers, effectively creating a transatlantic bridge for its newly acquired capabilities.

Fusing Electronics and Polymers: The Core of MedTech Innovation

The true power of this acquisition lies in the fusion of disparate but complementary technologies. Kimball brings the "brains" — the complex electronics, sensors, and connectivity. Helvoet brings the "body" — the highly specialized, precision-molded polymer and elastomer components that contain, channel, and interact with biological materials. This combination is essential for the future of MedTech, particularly in microfluidics, advanced diagnostics, and targeted drug delivery.

Helvoet is not a simple plastics molder. The company is a recognized leader in highly automated micro-molding and precision injection molding, holding critical certifications like ISO 13485 for medical devices. Its expertise in creating polymer-based microfluidic components—tiny "lab-on-a-chip" systems that can perform complex diagnostic tests—is a core asset. This is the physical backbone for the point-of-care testing revolution, enabling rapid analysis of fluids outside of a traditional laboratory. Helvoet’s involvement in the Flow Alliance, a consortium dedicated to advancing microfluidic technologies, substantiates its reputation as an innovator.

By integrating this "robust materials expertise" and "design and engineering savvy," as Hogenkamp described it, Kimball can now offer end-to-end solutions. A client developing a new smart inhaler or a wearable diagnostic patch no longer needs to source the electronics from one partner and the precision polymer housing or microfluidic chip from another. The combined entity can co-develop the entire system, from the electronic controller to the drug-delivery mechanism, streamlining development and accelerating time-to-market. This integrated approach is what the medical industry, facing increasing complexity and regulatory hurdles, desperately needs. Helvoet’s leadership, including Hogenkamp, will remain to steer this integration, ensuring its specialized culture of engineering excellence is woven into Kimball's larger operational fabric.

This merger is a forward-looking statement on where manufacturing value is heading. It’s no longer just about assembling components efficiently; it’s about mastering the critical, and often proprietary, materials and processes that enable next-generation systems to function. Kimball Electronics has secured a vital piece of that puzzle, positioning itself not merely as a manufacturer, but as an architect of the physical networks that will define the future of health.